IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

Ajou University School of Medicine

Status and phase

Unknown

Phase 3

Conditions

Asthma

Treatments

Drug: Immune Globulin

Study type

Interventional

Funder types

Other

Identifiers

NCT01992328

MED-CT4-12-405

Details and patient eligibility

About

Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

Full description

Patients Registration

•It is required to ensure that the patients meet the inclusion criteria for this clinical trial, are free from any items of exclusion criteria, are explained about the participation in the clinical trial along with the informed consent forms.

Procedure

•six months once a month intravenous immunoglobulin (400mg/kg/4weeks)

Enrollment

30 estimated patients

Sex

All

Ages

16 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient from over 16 years to under 75 years
Patients diagnosed with asthma over six months ago
immunoglobulin G subtypes who were diagnosed with immune deficiency
more than 2 years Upper and lower respiratory tract infections

, and asthma exacerbations in this regard.
① calculated creatinine clearance ≧ 50ml/min
- ALT and AST <x 3 times the upper limit of normal
  - ALP <x 3 times the upper limit of normal
    - total bilirubin <x 1.5 times the upper limit of normal

Exclusion criteria

within six months of the onset of the experiment who received immunoglobulin therapy
immune globulin for those with a history of hypersensitivity reactions
six months ago, another clinical trial participants.
Systemic steroids and immunomodulators, such as asthma control that may affect the resources required drug administration.
pregnant or lactating women.